The Filing Desk

Pfizer

PFE · NYSE · Health Care · Financials, fiscal 2016 to 2025

PFE · Last close · November 19, 2026
$27.54
Value Pfizer yourself

Pfizer's revenue fell 1.6% to $62.6 billion in fiscal 2025. Its net margin was 12.4%, down from 12.6% a year earlier. Free cash flow was $9.1 billion, down 7.7%. It paid out $9.8 billion in dividends and buybacks, 108% of free cash flow. The diluted share count rose 0.2%.

PFIZER INC Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0000078003-26-000026 Updated
Revenue
$62.6B
1.6%
Net margin
12.4%
0.2 pts
Net income
$7.8B
3.2%
Free cash flow
$9.1B
7.7%
Return on capital
7.2%
0.3 pts
Market cap
$158.4B
Nov 19 close
P/E
39.3x
On $0.70 EPS, 4 qtrs

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Pfizer does

Pfizer discovers, develops, makes and sells prescription medicines and vaccines, and supplies them to about 200 countries and territories. Its products include Eliquis, part of its internal medicine portfolio, vaccines such as the Prevnar family, Comirnaty and Abrysvo, the COVID-19 treatment Paxlovid, and cancer drugs such as Ibrance, Xtandi and Padcev. It sells its medicines mainly to wholesalers, and also directly to retailers, hospitals, clinics, pharmacies and government agencies.

Most of Pfizer's revenue comes from making and selling these products, and Biopharma is its only reportable segment. It also runs PC1, which develops and manufactures drugs for other companies under contract. In 2025, 12 products each brought in more than $1 billion, together 65% of total revenue; Eliquis alone was 13%. Revenue from outside the U.S. was $25.5 billion, or 41% of the total. Pfizer says it competes with other global drug companies, smaller research companies, and makers of generic drugs and biosimilars, which are close, lower-cost versions of biologic medicines.

Pfizer employed about 75,000 people at the end of 2025. In November 2025 it bought Metsera, a company developing medicines for obesity and related heart and metabolic diseases that are still in clinical trials. In 2025 it also decided to wind down Pfizer Ignite, which provided research services to biotech companies, and at the start of 2026 it set up a new Global Hospital and Biosimilars organization.

Its biggest risks, as it describes them

  • Losing sales when patents and exclusivity rights expire and cheaper generic drugs or biosimilars reach the market.
  • Its reliance on a small group of large products, such as Eliquis, and on a few large customers for much of its revenue.
  • Pressure on drug prices from governments, insurers and benefit managers, including its voluntary deal with the U.S. government to lower prices.
  • Acquisitions and other deals, such as its purchase of Metsera, may not bring the benefits it expects.
  • Competing products from other drugmakers that could cut into sales of its current and future medicines.
From Pfizer's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 1.7% a year and net income 0.8% a year, as buybacks cut the share count by 7%.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments24.019.27.311.910.3
Debt incl. finance leases37.835.471.863.664.6
Net debt (negative means net cash)13.916.364.551.754.3
Net debt to EBITDA0.5x0.4x6.8x2.9x3.2x
Debt to equity0.5x0.4x0.8x0.7x0.8x
Interest coverage19.8x29.1x1.5x3.6x3.8x
Current ratio1.4x1.2x0.9x1.2x1.2x
Quick ratio1.2x1.0x0.7x0.9x0.9x
US$ billions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project Pfizer's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Pfizer says to expect

  • Full year 2026: revenuesRaises full-year 2026 Revenue guidance (2) by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion from $60.5 to $62.5 billion previously.
  • Full year 2026: adjusted diluted EPSRaises and narrows full-year 2026 Adjusted (3) diluted EPS guidance (2) to a range of $2.95 to $3.05 from $2.80 to $3.00 previously.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 3, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $3.0 million of Pfizer shares on the open market, and 1 insider sold $134,661.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 12, 2026Albert BourlaChairman & CEO, DirectorBought38,000$26.34$1.0 millionForm 4
Aug 5, 2026Ronald E BlaylockDirectorBought39,231$25.46$998,821Form 4
Aug 5, 2026Mortimer J BuckleyDirectorBought37,632$25.52$960,369Form 4
Aug 5, 2026Jennifer B. DamicoSVP & ControllerSold3,278$25.40$83,261Form 4
Jun 9, 2026Jennifer B. DamicoSVP & ControllerSold2,000$25.70$51,400Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 98 of 96 of 9
Rule of 40−33.1%22.3%12.8%
Altman Z''2.353.103.06
Accruals ratio−3.1%−2.1%−1.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailPassFail
Share count didn't risePassPassFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailFailPass
F-score4 of 98 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Pfizer side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PfizerFY25−1.6%—14.5%7.2%3.2x6
Johnson & JohnsonFY256.0%—20.9%28.6%0.7x4Compare
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
ModernaFY25−39.9%−158.1%−106.2%−65.4%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue52.852.540.840.941.781.3101.259.663.662.6
Revenue growth8.1%−0.5%−22.3%0.2%1.8%95.2%24.5%−41.1%6.8%−1.6%
Gross profit40.541.331.832.933.250.566.834.645.846.5
Research and development7.97.77.88.48.710.411.410.710.810.4
Operating income——————————
Net income7.221.311.216.09.222.031.42.18.07.8
Diluted EPS (US$)1.173.521.872.821.633.855.470.371.411.36
Diluted shares (millions)6,1596,0585,9775,6755,6325,7085,7335,7095,7005,713
Cash flow
Cash from operations16.216.815.812.614.432.629.38.712.711.7
Capital expenditure1.82.02.02.02.22.73.23.92.92.6
Free cash flow14.414.813.810.512.229.926.04.89.89.1
Dividends paid7.37.78.08.08.48.79.09.29.59.8
Share buybacks5.05.012.28.90.00.02.00.00.00.0
Acquisitions18.41.00.010.90.00.023.043.40.06.9
Stock-based compensation0.70.80.90.70.81.20.90.50.90.8
Balance sheet at fiscal year end
Cash and short-term investments17.920.018.89.611.524.019.27.311.910.3
Debt incl. finance leases37.243.240.851.34.637.835.471.863.664.6
Total assets171.6171.8159.4167.6154.2181.5197.2226.5213.4208.2
Total liabilities111.8100.195.7104.190.8104.0101.3137.2124.9121.4
Shareholders' equity59.571.363.463.163.277.295.789.088.286.5
Margins and ratios
Gross margin76.7%78.6%78.0%80.3%79.6%62.1%66.0%58.1%71.9%74.3%
Operating margin——————————
Net margin13.7%40.5%27.3%39.2%22.0%27.0%31.0%3.6%12.6%12.4%
Free cash flow margin27.2%28.2%33.9%25.8%29.2%36.7%25.7%8.1%15.5%14.5%
Rule of 40 (growth + FCF margin)35.3%27.7%11.6%26.0%31.1%131.9%50.2%−33.1%22.3%12.8%
Return on capital11.0%15.6%5.4%12.8%9.9%32.0%32.0%2.5%7.6%7.2%
Return on equity11.6%32.6%16.6%25.3%14.5%31.3%36.3%2.3%9.1%8.9%
Return on assets4.3%12.4%6.7%9.8%5.7%13.1%16.6%1.0%3.6%3.7%
Net debt to EBITDA1.3x1.2x1.9x2.2x−0.5x0.5x0.4x6.8x2.9x3.2x
US$ billions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Pfizer's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Pfizer.